

# Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

---

## TRIAL

### (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT ID: NCT05907954 Phase: PHASE2 Sponsor: IDEAYA Biosciences Status: Active Not Recruiting

## SUMMARY

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

## KEY ELIGIBILITY CRITERIA

- \* Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
- \* Cohort 3 (patients with small UM tumors) - clinically diagnosed uveal (not iris) melanoma that is  $\leq 4$  mm in thickness requiring treatment
- \* Able to dose orally
- \* ECOG Performance status of 0-1
- \* No other significant underlying ocular disease
- \* Adequate organ function
- \* Not pregnant/nursing or planning to become pregnant. Willing to use birth control
- \* Previous treatment with a Protein Kinase C (PKC) inhibitor
- \* Concurrent malignant disease
- \* Active HIV infection or Hep B/C

Total sites: 18 | 0 currently recruiting